NasdaqGS - Nasdaq Real Time Price USD
Adaptive Biotechnologies Corporation (ADPT)
9.03
-0.24
(-2.59%)
At close: May 9 at 4:00:01 PM EDT
9.01
-0.02
(-0.22%)
After hours: May 9 at 7:59:05 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.25 | -0.21 | -0.87 | -0.62 |
| Low Estimate | -0.26 | -0.22 | -0.91 | -0.71 |
| High Estimate | -0.23 | -0.2 | -0.82 | -0.54 |
| Year Ago EPS | -0.29 | -0.22 | -1.02 | -0.87 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 8 | 8 |
| Avg. Estimate | 49.3M | 55.47M | 219.34M | 264.15M |
| Low Estimate | 46.98M | 54.2M | 213.7M | 243.5M |
| High Estimate | 52.91M | 58.05M | 225.94M | 279.2M |
| Year Ago Sales | 43.19M | 46.44M | 178.96M | 219.34M |
| Sales Growth (year/est) | 14.14% | 19.45% | 22.57% | 20.43% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.33 | -0.27 | -0.24 | -0.31 |
| EPS Actual | -0.29 | -0.22 | -0.23 | -0.2 |
| Difference | 0.04 | 0.05 | 0.01 | 0.11 |
| Surprise % | 12.02% | 19.84% | 5.17% | 35.48% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.25 | -0.21 | -0.87 | -0.62 |
| 7 Days Ago | -0.25 | -0.19 | -0.92 | -0.65 |
| 30 Days Ago | -0.25 | -0.19 | -0.91 | -0.64 |
| 60 Days Ago | -0.25 | -0.19 | -0.91 | -0.64 |
| 90 Days Ago | -0.23 | -0.2 | -0.86 | -0.6 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | 1 | -- | -- |
| Down Last 30 Days | -- | 1 | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ADPT | 14.83% | 3.98% | 15.33% | 27.75% |
| S&P 500 | 12.66% | 3.22% | 7.99% | 13.82% |
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 5/6/2025 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 5/5/2025 |
| Maintains | Goldman Sachs: Buy to Buy | 5/2/2025 |
| Upgrade | Goldman Sachs: Neutral to Buy | 3/21/2025 |
| Reiterates | Piper Sandler: Overweight to Overweight | 2/20/2025 |
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 2/13/2025 |
Related Tickers
FULC Fulcrum Therapeutics, Inc.
5.37
-0.74%
BEAM Beam Therapeutics Inc.
17.41
+0.93%
SLGL Sol-Gel Technologies Ltd.
7.85
+1.55%
CRMD CorMedix Inc.
11.66
-3.08%
KTTA Pasithea Therapeutics Corp.
0.8310
-13.44%
DNA Ginkgo Bioworks Holdings, Inc.
7.76
-1.40%
IBO Impact BioMedical Inc.
0.5495
+10.45%
PLRZ Polyrizon Ltd.
0.3747
-36.58%
EDIT Editas Medicine, Inc.
1.4500
+4.32%
NTLA Intellia Therapeutics, Inc.
8.12
-1.93%